Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-mutated Ovarian Carcinoma

Overview

Journal Cancer Res

Specialty Oncology

Date 2009 Aug 6

PMID 19654294

Citations 179

Authors

Wataru Sakai

Elizabeth M Swisher

Celine Jacquemont

Kurapaty Venkatapoorna Chandramohan

Fergus J Couch

Simon P Langdon

Kaitlyn Wurz

Jake Higgins

Emily Villegas

Toshiyasu Taniguchi

Affiliations

Soon will be listed here.

Abstract

Acquired platinum resistance is a serious problem in the treatment of ovarian carcinomas. However, the mechanism of the drug resistance has not been elucidated. Here, we show functional significance of restoration of BRCA2 protein by secondary BRCA2 mutations in acquired drug resistance of BRCA2-mutated ovarian carcinoma. Three ovarian cancer cell lines (PEO1, PEO4, and PEO6) were derived from a BRCA2 mutation [5193C>G (Y1655X)] carrier with ovarian carcinoma with acquired cisplatin resistance and a secondary BRCA2 mutation [5193C>T (Y1655Y)] that canceled the inherited mutation. PEO1 was BRCA2 deficient and sensitive to cisplatin and a poly(ADP-ribose) polymerase inhibitor, AG14361, whereas PEO4 was resistant. PEO4 and PEO6, derived from ascites at the time of relapse with cisplatin resistance, had the secondary mutation and were BRCA2 proficient. In vitro cisplatin/AG14361 selection of PEO1 led to restoration of BRCA2 due to another secondary BRCA2 mutation. BRCA2 depletion sensitized BRCA2-restored PEO1 clones and PEO4 to cisplatin/AG14361. Thus, restoration of BRCA2 due to secondary BRCA2 mutation is involved in acquired drug resistance of BRCA2-mutated ovarian carcinoma.

Citing Articles

Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability.

Whalen J, Earley J, Wisniewski C, Mercurio A, Cantor S Nat Cancer. 2025; 6(2):278-291.

PMID: 39838098 DOI: 10.1038/s43018-024-00902-1.

Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage.

Szmyd R, Casolin S, French L, Manjon A, Walter M, Cavalli L Nat Cell Biol. 2025; 27(1):59-72.

PMID: 39805921 PMC: 11735404. DOI: 10.1038/s41556-024-01557-x.

Clinically Significant and Germline Variants in Breast Cancer-A Single-Center Experience.

Plesea R, Riza A, Ahmet A, Gavrila I, Mitut A, Camen G Cancers (Basel). 2025; 17(1.

PMID: 39796670 PMC: 11718772. DOI: 10.3390/cancers17010039.

Low expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer.

Qiu Z, Sigh D, Liu Y, Prasad C, Bean N, Yan C Theranostics. 2024; 14(19):7450-7469.

PMID: 39659585 PMC: 11626944. DOI: 10.7150/thno.96879.

Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents.

Caggiano R, Prokhorova E, Duma L, Schutzenhofer K, Lauro R, Catara G Neoplasia. 2024; 59:101092.

PMID: 39615107 PMC: 11648251. DOI: 10.1016/j.neo.2024.101092.

References

Agarwal R, Kaye S . Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3(7):502-16. DOI: 10.1038/nrc1123. View

Hilton J, Geisler J, Rathe J, DeYoung B, Buller R . Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002; 94(18):1396-406. DOI: 10.1093/jnci/94.18.1396. View

Ashworth A . A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008; 26(22):3785-90. DOI: 10.1200/JCO.2008.16.0812. View

Farrugia D, Agarwal M, Pankratz V, Deffenbaugh A, Pruss D, Frye C . Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res. 2008; 68(9):3523-31. PMC: 2936780. DOI: 10.1158/0008-5472.CAN-07-1587. View

Yuan S, Lee S, Chen G, Song M, Tomlinson G, Lee E . BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 1999; 59(15):3547-51. View

Wu K, Hinson S, Ohashi A, Farrugia D, Wendt P, Tavtigian S . Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 2005; 65(2):417-26. View

Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani S . Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995; 10(8):1673-5. View

Bhattacharyya A, Ear U, Koller B, Weichselbaum R, Bishop D . The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000; 275(31):23899-903. DOI: 10.1074/jbc.C000276200. View

Taniguchi T, Tischkowitz M, Ameziane N, Hodgson S, Mathew C, Joenje H . Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003; 9(5):568-74. DOI: 10.1038/nm852. View

10.

Moynahan M, Pierce A, Jasin M . BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001; 7(2):263-72. DOI: 10.1016/s1097-2765(01)00174-5. View

11.

Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S . Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008; 26(1):20-5. DOI: 10.1200/JCO.2007.11.6905. View

12.

Wolf C, Hayward I, Lawrie S, Buckton K, McIntyre M, Adams D . Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer. 1987; 39(6):695-702. DOI: 10.1002/ijc.2910390607. View

13.

Edwards S, Brough R, Lord C, Natrajan R, Vatcheva R, Levine D . Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008; 451(7182):1111-5. DOI: 10.1038/nature06548. View

14.

Neuhausen S, Marshall C . Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 1994; 54(23):6069-72. View

15.

Gudmundsson J, Johannesdottir G, Bergthorsson J, Arason A, Ingvarsson S, Egilsson V . Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res. 1995; 55(21):4830-2. View

16.

Swisher E, Sakai W, Karlan B, Wurz K, Urban N, Taniguchi T . Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008; 68(8):2581-6. PMC: 2674369. DOI: 10.1158/0008-5472.CAN-08-0088. View

17.

Langdon S, Lawrie S, Hay F, Hawkes M, McDonald A, Hayward I . Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 1988; 48(21):6166-72. View

18.

Chen P, Chen C, Chen Y, Xiao J, Sharp Z, Lee W . The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A. 1998; 95(9):5287-92. PMC: 20253. DOI: 10.1073/pnas.95.9.5287. View

19.

Sakai W, Swisher E, Karlan B, Agarwal M, Higgins J, Friedman C . Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008; 451(7182):1116-20. PMC: 2577037. DOI: 10.1038/nature06633. View